Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion-Reference-Cited by-同舟云学术

Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion

Published:2023-12 Issue: Volume:1821 Page:148613
ISSN:0006-8993
Container-title:Brain Research
language:en
Short-container-title:Brain Research

Author:

Flores Andrew J.^ORCID,Bartlett Mitchell J.^ORCID,Seaton Blake T.^ORCID,Samtani Grace,Sexauer Morgan R.,Weintraub Nathan C.^ORCID,Siegenthaler James R.^ORCID,Lu Dong,Heien Michael L.,Porreca Frank^ORCID,Sherman Scott J.,Falk Torsten^ORCID

Funder

Achievement Rewards for College Scientists Foundation

Art Jewelry Forum

National Institutes of Health

University of Arizona

Publisher

Elsevier BV

Subject

Developmental Biology,Neurology (clinical),Molecular Biology,General Neuroscience

Reference85 articles.

1. Fast-scan controlled-adsorption voltammetry for the quantification of absolute concentrations and adsorption dynamics;Atcherley;Langmuir,2013

2. Enhanced Preproenkephalin-B-Derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-Induced dyskinesia;Aubert;Biological Psychiatry,2007

3. Long-term effect of sub-anesthetic ketamine in reducing l-DOPA-induced dyskinesias in a preclinical model;Bartlett;Neuroscience Letters,2016

4. Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia;Bartlett;Experimental Neurology,2020

5. Highly-selective μ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model;Bartlett;BMC Research Notes,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model;Neuropharmacology;2024-10

2. Endogenous opiates and behavior: 2023;Peptides;2024-09